oligomer-specific i-bodies (Crossbeta/AdAlta)

N/A

Report date: 2025/01/26 17:31:40

Base Information

Drug Nameoligomer-specific i-bodies (Crossbeta/AdAlta)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlandsAustralia and New Zealand
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCrossbeta Biosciences BV
China Registration ClassN/A

Develop Information

Active CompaniesAdAlta Pty LtdCrossbeta Biosciences BV
Inactive CompaniesN/A
Active IndicationsAlzheimer Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A